Kite: Two-Year Data for Lymphoma Combo Presented at ASH

-- 39 Percent of Patients in Ongoing Response Two Years after a Single Infusion of Yescarta in the ZUMA-1 Study; Median Overall Survival was Not Reached --

-- Data Presented at the Annual Meeting of the American Society of Hematology (ASH) and Simultaneously Published in The Lancet Oncology --

Kite, a Gilead Company (Nasdaq: GILD), announced two-year efficacy and safety data from the pivotal ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of two years after a single infusion of Yescarta (median follow up of 27.1 months), 39 percent of patients were in an ongoing response. This updated analysis with at least 24 months of follow-up was presented at the Annual Meeting of the American Society of Hematology (ASH; Abstract #2967) and simultaneously published in The Lancet Oncology.
https://www.streetinsider.com/Press+Releases/Kite+Announces+Two-Year+Data+for+Yescarta%C2%AE+%28Axicabtagene+Ciloleucel%29+in+Patients+With+Refractory+Large+B-Cell+Lymphoma/14881651.html